Yuval Cohen, PhD, CEO of Corbus Pharmaceuticals discusses the Development Award from the Cystic Fibrosis Foundation. The Development Award enables Corbus to execute its Phase 2b study of its novel, oral, pro-resolving drug lenabasum in approximately 415 people with cystic fibrosis who are 12 years and older and at increased risk for pulmonary exacerbations. Pulmonary exacerbations are severe inflammatory events in CF which are associated with acute worsening of respiratory signs and symptoms and sometimes irreversible loss of lung function.
